Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

Diabetic Medicine

Volumn 22, Issue 7, 2005, Pages 907-913

  Wulffele M G ^a   Kooy, Adriaan ^a   Lehert, P ^b   Betst, D ^c   Donker, A J M ^d,e   Stehouwer, C D A ^d,e  

^a Bethesda General Hospital   (Netherlands)

^b Facultes Universitaires Catholiques de Mons   (Belgium)

^c Merck BV   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

24 h ambulatory blood pressure monitoring; Blood pressure; Metformin; Randomized controlled trial; Type 2 diabetes

Indexed keywords

INSULIN; METFORMIN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HEART RATE; HUMAN; INFORMED CONSENT; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; TIME FACTORS;

EID: 21944432449     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01554.x     Document Type: Article

References (51)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8-13.
2. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55: 845-855.
3. Gans RO, Bilo HJ, Nauta JJ, Heine RJ, Donker AJ. Acute hyperinsulinemia induces sodium retention and a blood pressure decline in diabetes mellitus. Hypertension 1992; 20: 199-209.
4. Ridray S. Hyperinsulinemia and smooth muscle cell proliferation. Int J Obes Relat Metab Disord 1995; 19: S39-51.
5. Tack CJ, Smits P, Willemsen JJ, Lenders JW, Thien T, Lutterman JA. Effects of insulin on vascular tone and sympathetic nervous system in NIDDM. Diabetes 1996; 45: 15-22.
6. Sechi LA, Bartoli E. Molecular mechanisms of insulin resistance in arterial hypertension. Blood Press Suppl 1996; 1: 47-54.
7. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316-320.
8. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
9. Prospective UK Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
10. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
11. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999; 48: 2414-2421.
12. Jackson RA, Hawa MI, Jaspan JB, Sim BM, Disilvio L, Featherbe D et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987; 36: 632-640.
13. Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993; 42: 1217-1222.
14. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181-187.
15. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387-1390.
16. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ, Vara E, Calle JR, Munguira ME et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabetes Metab 1995; 21: 256-260.
17. Fanghanel G, Sanchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 1996; 19: 1185-1189.
18. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-629.
19. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated MDDM patients with suboptimal metabolic control. Diabetes Care 1998; 21: 701-705.
20. Schäfers RF. Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 2003; 29: 62-70.
21. Diabetes Prevention Program Research Group. Impact of lifestyle and metformin therapy on cardiovascular (CVD) risk factors and events in the Diabetes Prevention Program. Diabetes 2003; 52: A169.
22. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182-188.
23. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991; 14: 342-344.
24. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
25. Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-2140.
26. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
27. van Binsbergen JHGLMG, van den Hoogen J. NHG-standaard hypertensie. Huisarts en Wetenschap 1991; 34: 551-557.
28. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. Br Med J 2001; 322: 531-536.
29. Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate, and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Int Med 2003; 254: 455-463.
30. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992; 11: 1685-1704.
31. Sundaresan P, Lykos D, Daher A, Diamond T, Morris R, Howes LG. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes Care 1997; 20: 692-697.
32. Uehara MH, Kohlmann NEB, Zanella MT, Ferreira SRG. Metabolic and hemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 2001; 3: 319-325.
33. Gans RO, Donker AJ. Insulin and blood pressure regulation. J Intern Med Suppl 1991; 735: 49-64.
34. Lim U, Cassano PA. Homocysteine and blood pressure in the third National Health and Nutrition Examination Survey, 1988-94. Am J Epidemiol 2002; 156: 1105-1113.
35. O'Brien E, O'Malley K, Cox J, Stanton A. Ambulatory blood pressure monitoring in the evaluation of drug efficacy. Am Heart J 1991; 121: 999-1006.
36. Nielsen FS, Gaede P, Vedel P, Pedersen O, Parving HH. White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy. Diabetes Care 1997; 20: 859-863.
37. Bottini PB, Carr AA, Rhoades RB, Prisant LM. Variability of indirect methods used to determine blood pressure. Office vs mean 24-hour automated blood pressures. Arch Intern Med 1992; 152: 139-144.
38. Prospective UK Diabetes Study (UKPDS) Group. A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes (UKPDS 28). Diabetes Care 1998; 21: 87-92.
39. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19: 64-66.
40. Schneider J. Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. Diabetes Metab 1991; 17: 185-190.
41. Yki-Jarvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999; 130: 389-396.
42. 1c. IOEZ Study Group. Diabetes Care 2000; 23: 1236-1241.
43. Cefalu WT, Schneider DJ, Carlson HE, Migdal P, Gan Lim L, Izon MP et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care 2002; 25: 2123-2128.
44. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002; 4: 201-208.
45. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-1665.
46. Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IR. One-year comparatiye trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab 1994; 20: 394-400.
47. Wulfelé MG, Kooy A, De Zeeuw D, Stehouwer CDA, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Int Med 2004; 256: 1-14.
48. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-749.
49. Melchior WR, Jaber LA. Metformin: an antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother 1996; 30: 158-164.
50. Bell PM, Hadden DR. Metformin. Endocrinol Metab Clin North Am 1997; 26: 523-537.
51. Grant PJ. The effects of metformin on cardiovascular risk factors. Diabetes Metab Rev 1995; 11: S43-50.